Zenobia Therapeutics, a newly formed private company focusing on diseases that affect limited populations not normally pursued by larger companies, began its initial research efforts this month.
Founded in June, the company uses high-throughput structural biology and fragment-based lead discovery to find treatments for such illnesses as Parkinson's disease, Huntington's disease and muscular dystrophy.
Dr. Vicki Nienaber is president and founder. She previously was with ActiveSight, SGX Pharmaceuticals and Abbott Laboratories.
Zenobia is located at 505 Coast Blvd.